In conclusion, our study demonstrates that CXorf61 fulfils the requirements of an ideal target for cancer immunotherapy as it is cancer–cell selective, immunogenic and expressed at high level and frequency in TNBC tumors. The gene discussed is CT83; the disease is cancer.